The chemistry behind the new agent is as intriguing as its biological performance. Rather than simply tweaking the fluorouracil scaffold, the team constructed a library of fourteen compounds in which the 5-FU core was conjugated to phosphonium groups, positively charged chemical motifs that are drawn to the negative electrical potential that exists across the inner membrane of mitochondria, the energy factories of cells. This design strategy, sometimes exploited in mitochondrial-targeting drugs, was intended to ferry the cytotoxic payload more effectively into the cellular compartments where pro-survival signaling is orchestrated. When the researchers screened their library against prostate cancer cells, one candidate separated decisively from the pack. EB-18 displayed sub-micromolar cytotoxicity against both PC-3 cells, which lack the androgen receptor, and C4-2 cells, a model of castration-resistant prostate cancer in which the androgen receptor remains active. That dual potency matters, because castration-resistant prostate cancer that no longer responds to androgen-deprivation therapy represents one of the most stubborn clinical challenges in urologic oncology.

Prostate cancer was only the beginning. The investigators extended their testing across a panel of malignant solid-tumor cell lines from other organs, and EB-18 retained its killing power, supporting the team’s description of the compound as a candidate for pan-cancer application. In laboratory assays designed to mimic key stages of tumor aggression, the molecule inhibited cell proliferation, impaired cell migration, and suppressed the growth of three-dimensional tumor spheroids, which are considered more faithful stand-ins for real tumors than flat layers of cells. When the researchers peered into the treated cells, they found the hallmarks of a coordinated self-destruction program: perturbation of the cell cycle, the tightly regulated sequence of events by which cells duplicate their DNA and divide, followed by apoptosis, the programmed cell death that cancer cells so often evade.

The mechanistic story that emerged from these studies is layered and, in several respects, unexpected for a 5-FU descendant. Classic 5-FU works largely by masquerading as a normal DNA and RNA building block, poisoning nucleotide synthesis. EB-18, by contrast, appears to attack cancer cells on multiple fronts simultaneously. The compound disrupted survival signaling associated with HSP27, a heat shock protein that tumor cells rely on to buffer stress and resist chemotherapy-induced death. HSP27 has long interested oncologists precisely because elevated levels of the protein correlate with poor treatment outcomes in several cancers; indeed, a corresponding author of the new study holds patents on an antisense inhibitor of HSP27 previously developed for clinical use. EB-18’s ability to interfere with this protective machinery at the small-molecule level rather than through genetic silencing represents a different route to the same therapeutic vulnerability.

The compound’s second major target proved equally consequential. EB-18 promoted the ubiquitination of DDX5, a DNA helicase protein involved in transcription and cell proliferation, tagging it for destruction by the proteasome, the cellular waste-disposal system that shreds proteins marked with ubiquitin chains. Loss of DDX5 crippled downstream AKT/mTOR signaling, a central growth pathway that tumors co-opt to sustain unrelenting proliferation. In parallel, the researchers observed that EB-18 increased levels of γ-H2AX, a molecular beacon that flags double-strand breaks in DNA, while reducing expression of Ku70 and Ku80, proteins that help repair precisely those breaks. In other words, the drug appears to inflict severe DNA damage while simultaneously dismantling the repair crews that would normally rescue the cell, a one-two combination that pushes malignant cells past the point of no return. In androgen receptor-positive C4-2 cells, EB-18 additionally drove down expression of the androgen receptor itself, striking at the engine of castration-resistant disease.

What elevates the study beyond conventional cell-culture pharmacology is the rigor of its disease models. The team tested EB-18 in patient-derived organoids, miniature tumors grown from tissue donated by people with prostate cancer, which preserve much of the cellular heterogeneity and drug responsiveness of the original malignancies. The compound retained its activity in these organoids and, critically, in multidrug-resistant castration-resistant prostate cancer cells, the kind of refractory disease that clinicians most dread encountering. Patient tissue for this work was obtained through the Biological Resource Centre of the Marseille Public Hospital System with written informed consent, under protocols certified to international biobanking standards, lending the findings a translational credibility that laboratory models alone cannot provide.

The final preclinical proof came from living animals. In mouse xenografts bearing PC-3 prostate tumors, treatment with EB-18 significantly inhibited tumor growth, confirming that the compound’s cellular effects translate into tangible anti-tumor activity in vivo. According to the authors, EB-18 demonstrated superior anticancer activity compared with 5-FU itself and with clinically used chemotherapies including docetaxel, cabazitaxel, and mitoxantrone across the preclinical models examined. That comparison is striking, because docetaxel and cabazitaxel are the current workhorses of chemotherapy for metastatic castration-resistant prostate cancer, and both eventually fail as resistance develops. A single small molecule capable of matching or exceeding the performance of these agents, while retaining efficacy in multidrug-resistant cells, would represent a meaningful expansion of the therapeutic arsenal.

The research was carried out by a multidisciplinary team spanning several French institutions, including CNRS and INSERM research units in Marseille and the Institut Pasteur in Paris, and was supported by INSERM, the Ligue Nationale Contre Le Cancer, ITMO Cancer, and the Amidex Foundation, with additional funding under the France 2030 investment plan. The work emerges from a laboratory with a long-standing interest in HSP27 biology and its exploitation in cancer therapy, and the authors note commercial interests, including co-founding of a biotechnology company focused on precision medicine and nucleic acid therapeutics, alongside patent filings related to HSP27 inhibition. Such entanglements are common in translational oncology and underscore how close the scientists consider this molecule to be to real-world relevance, though they also signal the need for independent validation.

Considerable distance remains between a promising preclinical candidate and an approved medicine. EB-18 has not yet been tested in humans, and the authors themselves frame their findings as a rationale for further pharmacological, mechanistic, and translational evaluation rather than as a treatment ready for the clinic. Toxicology, pharmacokinetics, dosing, formulation, and safety profiling all lie ahead, along with the unpredictable attrition that claims most experimental drugs. Nevertheless, the study offers a compelling proof of concept: that a sixty-year-old chemotherapy scaffold, creatively re-engineered with mitochondrial-targeting chemistry and aimed at resistance-driving pathways such as HSP27 signaling, DDX5 degradation, and the DNA damage response, can be reborn as a broader, harder-to-defeat weapon. If subsequent development sustains the momentum reported here, EB-18 could eventually give oncologists a genuinely new option against tumors that have exhausted every currently available line of defense.

Subject of Research: A novel phosphonium-substituted 5-fluorouracil derivative, EB-18, developed as a pan-cancer chemotherapy candidate that improves antitumor efficacy and overcomes therapy resistance.

Article Title: A novel 5-FU derivative chemotherapy: a promising pan-cancer treatment to improve antitumor efficacy and overcome therapy resistance

Article References: Duong, Q. H., Khusnutdinova, E., Le, T. K., Hu, Y., Tran, T. T., Nail, V., Balasse, L., Dinh, T. D., Phan, T. T. U., Borie-Guichot, M., Baboudjian, M., Garzino, F., Guillet, B., Taïeb, D., Camplo, M., & Rocchi, P. (2026). A novel 5-FU derivative chemotherapy: a promising pan-cancer treatment to improve antitumor efficacy and overcome therapy resistance. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03826-z

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03826-z

Keywords: 5-fluorouracil, EB-18, chemotherapy, castration-resistant prostate cancer, drug resistance, HSP27, DDX5, AKT/mTOR signaling, DNA damage response, apoptosis, patient-derived organoids, xenograft models

The research team, led by Peiling Dai of the First Affiliated Hospital of Wenzhou Medical University along with colleagues across several Chinese institutions, focused on a group the authors abbreviate as EFLCBM: elderly female lung cancer patients with bone metastases. Rather than relying on broad staging categories that lump together wildly different patients, the team set out to build a nomogram—a visual scoring instrument that combines multiple clinical variables into a single personalized probability of survival. Nomograms have become increasingly popular in oncology precisely because they translate complex statistical models into something a physician can use at the bedside, weighing tumor characteristics, demographics, and treatment factors to estimate an individual patient’s risk.

The foundation of the study is the Surveillance, Epidemiology, and End Results database, the large population-based cancer registry maintained by the United States National Cancer Institute. From SEER, the researchers identified 3,194 elderly women with lung cancer that had metastasized to bone. To guard against the well-known pitfall of models that perform well only on the data used to build them, the team split the SEER cohort into a training set and an internal validation set, then added a genuinely independent check: 71 patients treated at their own medical institution formed an external validation cohort. This three-tiered structure—train, validate internally, validate externally—is considered the gold standard for demonstrating that a prediction tool has real-world rather than merely mathematical staying power.

Statistically, the work rested on Cox proportional hazards regression. The researchers first ran univariate analyses to screen candidate variables associated with overall survival, then multivariable analyses to isolate the independent prognostic factors—those variables that retained predictive power even after accounting for everything else. The significant factors were then assembled into the nomogram, with each variable assigned a weighted score reflecting its contribution to survival risk. The endpoint the model targets is overall survival, estimated at 12, 18, and 24 months after diagnosis, giving clinicians a rolling window of personalized prognosis rather than a single static number.

The performance metrics are where the study earns its credibility. The area under the curve, or AUC, a standard measure of a model’s ability to distinguish patients who survive from those who do not, reached 0.752, 0.766, and 0.786 for 12-, 18-, and 24-month survival respectively in the training cohort. Values above 0.75 are generally regarded as indicating useful discrimination, and the model held up well beyond its own training data: AUCs of 0.743, 0.727, and 0.716 in the internal validation cohort, and 0.679, 0.633, and 0.690 in the external validation cohort. The drop in the external cohort is expected and honest—no prediction model transfers perfectly between institutions—but the figures suggest the tool retains meaningful signal when applied to patients it has never seen.

Discrimination alone, however, is not enough. A model can rank patients correctly yet still produce biased absolute probabilities, so the team examined calibration curves, which plot predicted survival against observed survival. Across the SEER cohorts and the external institutional cohort, the calibration curves showed that the model’s predictions tracked closely with what actually happened to patients, a sign that the risk estimates are not merely rank-ordered but quantitatively trustworthy. The researchers also applied decision curve analysis, a relatively recent technique that quantifies the clinical net benefit of acting on a model’s predictions across a range of threshold probabilities. Here the nomogram delivered perhaps its most persuasive result: across a wide span of clinically relevant thresholds, acting on the model yielded more net benefit than treating everyone, treating no one, or relying on simpler default strategies.

Beyond prediction, the study converted the nomogram into a practical risk classification system, stratifying patients into groups whose survival trajectories differed markedly on Kaplan-Meier analysis. This stratification then served a second, therapeutically significant purpose: identifying which treatment modality best serves which risk group. The subgroup analysis produced a clear pattern. For patients classified as low risk, chemotherapy emerged as the recommended mainstay of treatment, while for high-risk patients, the early use of radiotherapy appeared more beneficial. In a field where treatment of elderly patients with metastatic disease has often been guided by one-size-fits-all instincts—or by therapeutic nihilism—this finding offers an evidence-based framework for tailoring intensity and modality to the individual.

The implications extend beyond the specific population studied. Elderly women with lung cancer have historically been underrepresented in clinical trials, leaving their clinicians to extrapolate from evidence gathered in younger, fitter, and predominantly male cohorts. A tool built explicitly from and for this population closes part of that gap. It also arrives at a moment when radiotherapy and systemic therapy for bone metastases are both evolving rapidly, making the question of sequencing—who gets radiation first, who gets drugs first—more pressing than ever. The authors’ risk-based framework gives oncologists a principled starting point for those conversations, potentially sparing low-risk patients the side effects of treatments unlikely to help them while accelerating high-risk patients toward interventions that may palliate pain and prevent skeletal complications.

The study, which was retrospectively conducted and therefore exempted from individual informed consent by the ethics committee of the First Affiliated Hospital of Wenzhou Medical University, does carry the inherent limits of registry data, and the modest size of the external cohort of 71 patients means the external validation should be replicated elsewhere. Still, the authors conclude that their nomogram demonstrates good discrimination, calibration, and clinical benefit, and that the accompanying risk classification system successfully identifies the best beneficiary populations for radiotherapy and chemotherapy among elderly female lung cancer patients with bone metastases. For a growing group of patients whose prognosis has long been described in grim generalities, the message of this research is refreshingly specific: with the right data, an individualized forecast—and an individualized treatment plan—is now within reach.

Subject of Research: A prognostic nomogram for predicting survival outcomes in elderly female lung cancer patients with bone metastases

Article Title: Development and validation of a nomogram for predicting disease outcomes in elderly females with lung cancer metastatic to the bone

Article References: Dai, P., Chen, S., Yang, B., Chen, K., Huang, Z., & Liu, J. (2026). Development and validation of a nomogram for predicting disease outcomes in elderly females with lung cancer metastatic to the bone. BMC Cancer. https://doi.org/10.1186/s12885-026-16991-3

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16991-3

Keywords: lung cancer, bone metastases, nomogram, prognosis, SEER database, chemotherapy, radiotherapy, elderly women, overall survival, decision curve analysis, risk classification, BMC Cancer

Drug-tolerant persister cells are a phenomenon increasingly recognized across many cancer types. These cells do not carry permanent resistance mutations; instead, they enter a reversible, slow-survival state that allows them to ride out treatment. Once chemotherapy stops, they can regrow into a full tumor, causing local recurrence that is often harder to treat than the original disease. In osteosarcoma, where aggressive multi-drug chemotherapy combined with surgery has improved survival significantly over past decades, relapse after apparently complete treatment remains a devastating clinical problem. The team behind the new study, led by researchers at the Eighth Affiliated Hospital of Sun Yat-sen University in Shenzhen, suspected that the unique biology of the bone microenvironment might be actively shaping this persister state rather than simply housing it.

The investigation began with a basic observation: when osteosarcoma cells were exposed to chemotherapy drugs in the laboratory, the surviving DTP cells showed consistently elevated levels of intracellular calcium. This finding immediately pointed toward the bone environment itself. Bone is, by definition, a mineral-rich tissue, saturated with calcium salts, and osteosarcoma cells live and evolve in that milieu. The researchers found that calcium buildup in persisting cells was accompanied by increased expression of ORAI3, a calcium channel protein involved in store-operated calcium entry, one of the main mechanisms by which cells replenish their internal calcium reserves. Elevated ORAI3 activity effectively opened the gates for calcium to flood into the persister cells, and that calcium flood turned out to be far from incidental.

Tracing the pathway downstream, the team showed that heightened calcium signaling promoted the nuclear translocation of NFAT4, a member of the nuclear factor of activated T cells family of transcription factors. Once inside the nucleus, NFAT4 acted on the gene encoding PINK1, PTEN-induced kinase 1, a well-known master regulator of mitophagy, the cellular process that identifies damaged mitochondria and directs their removal. In the persister cells, the result was a surge in PINK1-driven mitophagy. Rather than accumulating broken, dysfunctional mitochondria that would produce toxic reactive oxygen species and trigger cell death under chemotherapy stress, the DTP cells were continuously cleaning house, pruning away damaged mitochondria and preserving a pool of healthy ones.

The metabolic consequences of this mitochondrial quality control proved central to the survival strategy. Metabolic assays revealed that the persister cells maintained sustained tricarboxylic acid cycle activity and continued to rely on oxidative phosphorylation, the efficient mitochondrial process that generates cellular energy. This was a revealing finding, because many cancer cells under stress shift toward a less efficient, sugar-burning metabolism. The osteosarcoma persisters instead appeared to protect their oxidative powerhouses at all costs, and mitophagy was the mechanism that made this possible. By keeping mitochondrial homeostasis intact, the ORAI3–Ca²⁺–NFAT4–PINK1 axis ensured that the cells retained the energy production capacity needed to endure weeks of chemotherapeutic pressure without collapsing into metabolic failure.

To test whether this pathway mattered in living animals, the researchers engineered osteosarcoma xenografts carrying an inducible PINK1 knockdown system, allowing them to silence the gene at will. The results were striking in their timing. Before chemotherapy began, switching off PINK1 had no discernible effect on tumor growth; the cancer cells were perfectly viable. But once treatment started, tumors with silenced PINK1 showed reduced burden, and when chemotherapy was withdrawn, they regrew far more slowly than controls. In other words, PINK1 was not required for the tumor to exist, but it was essential for the tumor to survive chemotherapy and stage its comeback. Experiments in orthotopic bone tumors and lung metastasis models produced consistent results, reinforcing the conclusion that the pathway underpinned treatment tolerance across tumor settings.

The team then turned to pharmacological tools. GSK-7975 A, a small molecule that blocks ORAI-mediated calcium entry, proved capable of disrupting the axis at its source. Most notably, combining GSK-7975 A with chloroquine, an antimalarial drug that inhibits autophagic degradation, suppressed local recurrence in xenograft, orthotopic, and lung metastasis models. The logic of the combination is intuitive: the calcium channel blocker prevents the protective signal from being generated, while the autophagy inhibitor undermines the disposal machinery that persisters depend on. Together, the two agents deprived DTP cells of both the instruction and the equipment needed to maintain their mitochondrial shelter, leaving them vulnerable to chemotherapy they would otherwise survive.

Clinical evidence strengthened the case. Immunohistochemical analysis of human osteosarcoma tissues, comparing samples from patients who had received chemotherapy with those who had not, showed that ORAI3 and PINK1 expression was elevated after treatment, mirroring the laboratory findings. Single-cell and spatial transcriptomic analyses further supported the relevance of the axis in patient tumors, indicating that the calcium–mitophagy program is not merely a laboratory artifact but a feature of human disease. Given that both ORAI3 blockade and chloroquine-like compounds are already part of the pharmacological landscape, the pathway offers a plausible near-term target for clinical translation, potentially as an adjuvant strategy layered onto existing osteosarcoma chemotherapy regimens to eliminate the cells that seed recurrence.

The broader significance of the study lies in its reframing of the tumor microenvironment as an active participant in therapeutic failure. Rather than viewing recurrence simply as the outgrowth of resistant clones, the work suggests that bone’s defining biochemistry, its saturating calcium, hands osteosarcoma cells a ready-made survival program. It also connects two fields that rarely intersect: calcium channel biology and mitochondrial quality control, linked through NFAT4 as the molecular bridge. For a disease that disproportionately strikes adolescents and young adults, and where recurrence often carries a grim prognosis, the identification of a druggable axis that specifically disables persister cells during treatment represents a meaningful conceptual advance. If clinical studies confirm the animal findings, blocking ORAI3 or mitophagy could become a standard companion to chemotherapy, converting a treatment that currently leaves survivors vulnerable to relapse into one that clears the tumor down to its last resilient cell.

Subject of Research: A calcium-driven ORAI3–Ca²⁺–PINK1 mitophagy pathway that sustains drug-tolerant persister cells and local recurrence in osteosarcoma.

Article Title: Calcium-rich bone microenvironment promotes drug-tolerant persistence in osteosarcoma through ORAI3–Ca²⁺–PINK1–mitophagy axis

Article References: Li, H., Yu, H., Lu, Y., Liu, Y., Wu, W., Mi, R., Yang, W., Yuan, C., Yi, H., Gu, Y., Zhuang, J., & Ma, M. (2026). Calcium-rich bone microenvironment promotes drug-tolerant persistence in osteosarcoma through ORAI3–Ca²⁺–PINK1–mitophagy axis. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03828-x

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03828-x

Keywords: osteosarcoma, drug-tolerant persister cells, calcium signaling, ORAI3, PINK1, mitophagy, NFAT4, oxidative phosphorylation, local recurrence, chemotherapy, GSK-7975 A, chloroquine

The research, led by Hyman B. Muss of the University of North Carolina at Chapel Hill and Mina S. Sedrak of UCLA, together with colleagues at City of Hope and the Mayo Clinic, examined 251 women with early-stage breast cancer and 49 cancer-free controls. The team measured p16INK4a, a gene whose expression rises as cells enter senescence—a state of permanent growth arrest linked to aging and disease—and compared it against five DNA methylation clocks: Horvath, Hannum, PhenoAge, GrimAge, and the Dunedin Pace of Aging, known as mPoA. DNA methylation clocks estimate biological age from characteristic patterns of chemical tags on DNA that shift predictably over a lifetime.

The two biomarker families barely spoke to each other. Across both cancer patients and controls, correlations between T-cell p16 and the methylation clocks were weak, with correlation coefficients generally below 0.3. In the cancer cohort, p16 showed only modest associations with Hannum, PhenoAge, and GrimAge, and none at all with the Horvath clock or the Dunedin pace measure. The pattern held in the control group and in a separate cohort of younger patients, where the strongest relationship—between p16 and GrimAge—reached only a moderate correlation of 0.40. The Dunedin measure, which estimates the rate of aging rather than accumulated age, showed essentially no relationship with p16 anywhere.

That disconnect matters because researchers and clinicians increasingly rely on these tests to gauge whether diseases or treatments are accelerating aging, and to evaluate interventions meant to slow it down. If p16 and methylation clocks captured the same underlying biology, they could be used interchangeably. The new findings suggest they cannot. The authors argue that the two measures reflect fundamentally different aspects of aging: p16 tracks senescence within a specific immune cell population, while methylation clocks integrate epigenetic signals across the heterogeneous mixture of cell types found in whole blood. Differences in biological compartment, measurement scale, and clock design—all calibrated differently, some to chronological age and others to mortality risk—likely all contribute to the weak overlap.

The study also probed whether cancer itself leaves a measurable imprint on these markers. When the researchers plotted biomarker levels against chronological age, women with breast cancer did not differ from controls in p16, Hannum, Horvath, or the Dunedin pace measure. But two of the mortality-informed clocks told a different story: GrimAge and PhenoAge were both significantly higher in the cancer group, and the differences persisted after adjusting for race, ethnicity, and body mass index. The result aligns with a growing body of evidence that cancer is associated with physiological changes consistent with accelerated aging, while suggesting that standard epigenetic clocks are not uniformly sensitive to that signal.

The most striking results came from the longitudinal arm. In a subset of 48 women with early breast cancer who gave blood before and three to six months after adjuvant chemotherapy, p16 expression rose significantly, by an average of 0.7 log2 units—an increase the authors note is equivalent to roughly 10 to 20 years of chronological aging. Yet four of the five methylation clocks—Horvath, PhenoAge, GrimAge, and the Dunedin pace—showed no significant change over the same interval. Only the Hannum clock increased, and only modestly. When the team split patients into those whose p16 rose beyond assay precision and those whose did not, none of the epigenetic clocks changed in either group, underscoring that the chemotherapy signal seen in senescence markers simply was not mirrored in the methylation-based measures.

The findings complicate the interpretation of earlier studies. Some prior work reported epigenetic age acceleration after cancer treatment: one study of breast cancer survivors found those who received chemotherapy were biologically two to three years older than controls two to three years after treatment, and a small study of 18 patients reported acceleration of roughly 3.5 to 8 years after a single anthracycline-containing cycle, though that analysis lacked paired samples. Other research found clock changes only years or decades later, or no change at all depending on regimen and follow-up timing. The new data suggest methylation clocks are not blind to treatment-related aging effects, but may respond on a different timescale or capture different biological consequences than the rapid senescence response registered by p16.

The team also explored senescence-associated secretory phenotype proteins—inflammatory molecules shed by senescent cells that have been linked to morbidity and mortality. In 20 patients treated with doxorubicin-based chemotherapy, chemotherapy-induced increases in p16 correlated with rising levels of PARC, TNFRII, ICAM1, and TNF-alpha. Intriguingly, baseline p16 showed little to no association with baseline levels of these proteins, suggesting the link is driven by the chemotherapy itself. Together with prior work showing increased p16, DNA damage, and inflammatory markers in survivors over two years, the results paint a picture in which cytotoxic chemotherapy provokes a coordinated senescence and inflammatory response that current epigenetic clocks largely miss.

The authors are careful about the limits of their analysis. The longitudinal component was exploratory and small; the cross-sectional and longitudinal cohorts differed in age and sampling protocols; p16 and methylation were measured in different biological compartments; and chemotherapy-related shifts in immune cell composition can confound whole-blood methylation measures. The three-to-six-month follow-up window may also simply be too short for clocks that evolve over years. Treatment regimens were heterogeneous, mixing anthracycline and non-anthracycline approaches, though recent long-term follow-up found persistently elevated p16 regardless of regimen.

Even so, the message is clear and potentially consequential: the most popular biomarkers of biological aging are not interchangeable. Choosing between them requires knowing which aging process—and which timescale—a study actually cares about. For the millions of breast cancer survivors living with the long-term consequences of treatment, that distinction could shape how researchers track accelerated aging, design interventions such as exercise or senolytic drugs, and ultimately judge whether a therapy that cures cancer is also quietly aging the body that carries it.

Subject of Research: Comparison of cellular senescence marker p16INK4a and DNA methylation epigenetic clocks as biomarkers of biological aging in women with early breast cancer treated with chemotherapy

Article Title: p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Article References: p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer. (n.d.). https://doi.org/10.1007/s11357-026-02521-3

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02521-3

Keywords: p16INK4a, DNA methylation clocks, biological aging, cellular senescence, breast cancer, chemotherapy, epigenetic age, GeroScience, GrimAge, PhenoAge, biomarkers of aging, cancer survivors

Hepatocellular carcinoma remains one of the deadliest malignancies worldwide, ranking among the leading causes of cancer-related death. Its lethality stems largely from two clinical realities: a strong tendency to spread beyond the liver, and a stubborn resistance to conventional chemotherapeutic agents. Even as immunotherapy and targeted agents reshape the treatment landscape, many patients progress rapidly, and the molecular drivers of that progression have remained only partially mapped. The new findings add a critical piece to that map, positioning ApoA2 not as a passive biomarker but as an active participant in the tumor’s malignant behavior.

Apolipoproteins are best known for their role in lipid metabolism, shuttling cholesterol and triglycerides through the circulation. ApoA2 is a major constituent of HDL particles, and circulating levels of the protein have previously been associated with metabolic syndrome, cardiovascular disease, and, intriguingly, with altered risk profiles in several cancers. Epidemiological observations had hinted at connections between ApoA2 abundance and tumor behavior, but the mechanistic basis for such a link was unclear. The new study set out to determine whether ApoA2 is merely a correlate of disease severity or a genuine contributor to it.

Using hepatocellular carcinoma cell lines, animal models, and clinical tissue samples, the researchers found that ApoA2 expression is elevated in aggressive tumors and correlates with poor prognosis. When the team manipulated ApoA2 levels in laboratory models, the consequences were striking. Increasing ApoA2 enhanced the migratory and invasive capacity of cancer cells, while suppressing it markedly reduced metastatic potential. In mouse models of liver cancer, tumors with high ApoA2 activity spread more readily and responded poorly to chemotherapy, whereas lowering ApoA2 restored drug sensitivity and curtailed tumor dissemination.

The mechanistic heart of the paper lies in the HMGB1/IL-17A axis. HMGB1, or high-mobility group box 1, is a DNA-binding protein that normally resides in the nucleus, where it helps regulate gene expression and genome architecture. When cells are stressed, damaged, or activated by inflammatory signals, HMGB1 can be released into the extracellular space, where it acts as a danger signal, or alarmin, binding to receptors such as RAGE and Toll-like receptors to ignite inflammatory responses. The study demonstrates that ApoA2 promotes the secretion of HMGB1 from hepatocellular carcinoma cells, converting an intracellular housekeeping protein into an extracellular inflammatory messenger.

Once outside the cell, HMGB1 sets off a chain reaction. The researchers show that extracellular HMGB1 stimulates the production of interleukin-17A, a pro-inflammatory cytokine classically associated with Th17 immune cells but increasingly recognized as a product of the tumor microenvironment itself. IL-17A is known to fuel chronic inflammation, promote angiogenesis, and foster an immunosuppressive milieu that favors tumor growth. In this context, the ApoA2-HMGB1-IL-17A circuit appears to create a self-reinforcing inflammatory loop within and around the tumor, one that simultaneously drives cells toward invasive behavior and shields them from the cytotoxic effects of chemotherapeutic drugs.

The drug resistance component of the findings is particularly consequential. Chemotherapy for hepatocellular carcinoma has long been hampered by modest response rates, and understanding why some tumors shrug off treatment is a central question in the field. The study provides evidence that the HMGB1/IL-17A pathway activated by ApoA2 helps cancer cells survive drug-induced stress, likely through inflammatory survival signaling and alterations in the tumor microenvironment that blunt drug efficacy. When the researchers interfered with the axis, blocking HMGB1 or neutralizing IL-17A, the resistance phenotype weakened, suggesting that each node in the pathway represents a potential therapeutic target.

From a translational standpoint, the work carries several implications. First, ApoA2 could serve as a biomarker to identify patients whose tumors are predisposed to metastasis and treatment failure, allowing clinicians to stratify therapy more aggressively from the outset. Second, existing drugs or biologics that target IL-17A, some of which are already approved for inflammatory diseases such as psoriasis, could potentially be repurposed or adapted for hepatocellular carcinoma, either alone or in combination with chemotherapy or immunotherapy. Third, the identification of HMGB1 as a pivotal intermediary offers another intervention point, and HMGB1 inhibitors are an area of active pharmaceutical development.

The findings also resonate with a broader conceptual shift in cancer biology: the recognition that metabolic proteins and inflammatory circuits are deeply intertwined with malignant progression. Tumors do not evolve in isolation; they co-opt the body’s lipid transport machinery, danger-sensing systems, and immune signaling networks to advance their own agenda. The ApoA2/HMGB1/IL-17A axis is a vivid example of this co-option, linking a routine component of blood lipid particles to the inflammatory engine that powers metastasis and treatment resistance. It underscores why chronic inflammation of the liver, whether from viral hepatitis, alcohol, or fatty liver disease, creates such fertile ground for cancer, and why interrupting inflammatory signaling may be as important as attacking the cancer cells directly.

As with any preclinical study, important questions remain before the findings can change clinical practice. The precise molecular steps by which ApoA2 triggers HMGB1 release, the relative contributions of tumor cells versus immune cells to IL-17A production, and the safety of targeting this axis in patients with underlying liver disease all require further investigation. Human validation in large, prospective cohorts will be essential to confirm ApoA2’s prognostic value. Nevertheless, the study delivers a compelling and mechanistically grounded case that a familiar blood protein is an unexpected architect of liver cancer aggression, and it opens a concrete path toward therapies that could strip hepatocellular carcinoma of two of its most dangerous weapons: the ability to spread and the ability to survive treatment.

Subject of Research: The role of apolipoprotein A2 in promoting metastasis and drug resistance in hepatocellular carcinoma through the HMGB1/IL-17A inflammatory signaling axis.

Article Title: ApoA2 promotes tumor metastasis and drug resistance in hepatocellular carcinoma by activating the HMGB1/IL-17A axis

Article References: Fu, Z., Zhu, F., Fu, Z., Wang, C., Guan, T., Yuan, Y., Zhang, S., & Zhang, T. (2026). ApoA2 promotes tumor metastasis and drug resistance in hepatocellular carcinoma by activating the HMGB1/IL-17A axis. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03317-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03317-2

Keywords: ApoA2, hepatocellular carcinoma, HMGB1, interleukin-17A, metastasis, drug resistance, liver cancer, inflammation, tumor microenvironment, biomarker, cytokine signaling, chemotherapy

The scale of the problem the guidelines address is stark. Approximately 15 to 25 percent of colorectal cancer patients already have liver metastases when their cancer is first diagnosed, and a further 15 to 25 percent develop such metastases after curative resection of the primary tumor. Critically, 80 to 90 percent of these liver metastases are initially unresectable with curative intent. Left untreated, patients with colorectal liver metastases have a median survival of only 6.9 months, and the five-year survival rate for unresectable disease falls below 5 percent. By contrast, patients who achieve complete resection of their liver metastases, or reach a status of no evidence of disease, experience median survival of 35 to 60 months and five-year overall survival rates of 40 to 57 percent. This dramatic gap between the untreated and the successfully treated is precisely what the new guidelines are designed to close.

On the diagnostic front, the 2025 edition codifies a tiered imaging strategy. For every newly diagnosed colorectal cancer patient, liver ultrasound and contrast-enhanced abdominal computed tomography are recommended as routine screening tools, alongside serum tumor markers such as carcinoembryonic antigen and CA19-9. When ultrasound or CT findings are suspicious but inconclusive, the guidelines endorse supplemental testing with serum alpha-fetoprotein, contrast-enhanced liver ultrasound, and contrast-enhanced liver MRI. Liver-specific contrast-enhanced MRI earns a particularly strong endorsement because it demonstrates higher accuracy for detecting lesions smaller than one centimeter, a critical threshold since tiny metastases are the ones most easily missed and most consequential for surgical planning. PET-CT and PET-MRI are explicitly not recommended for routine use, reserved instead for selected clinical scenarios where additional information is genuinely needed.

The guidelines also formalize a rigorous surveillance program after radical resection of the primary colorectal tumor. Patients should undergo history-taking, physical examination, liver ultrasound and tumor marker testing every three to six months for the first two years, then every six months until five years, and annually thereafter. For patients with stage II and III disease, annual contrast-enhanced CT of the chest, abdomen and pelvis is recommended for three to five years. Electronic colonoscopy should be performed within one year of surgery, with repeat examination at three years and then every five years if no abnormalities are found. After patients achieve no evidence of disease status for liver metastases, the surveillance intensifies further, with tumor markers checked every three months for two years and abdominal imaging every three months during the same period, reflecting the high risk of recurrence in this population.

Perhaps the most consequential section of the 2025 update concerns molecular profiling. The guidelines recommend mismatch repair and microsatellite instability testing for all colorectal cancer patients, a recommendation grounded in the transformative role of immune checkpoint inhibitors in tumors with deficient mismatch repair or high microsatellite instability. RAS genotyping, covering exons 2, 3 and 4 of both KRAS and NRAS, is recommended for all patients with colorectal liver metastases, both for its prognostic value and its role in predicting response to anti-EGFR therapy. BRAF V600E mutation testing is endorsed as both a prognostic indicator and a guide to treatment selection, while HER2 testing is recommended for metastatic patients to inform post-progression decisions. The guidelines also acknowledge emerging biomarkers including tumor mutational burden, POLE and POLD1 mutations, NTRK fusions, RET rearrangements and c-MET alterations, and highlight circulating tumor DNA-based minimal residual disease assessment as a promising but not yet fully validated tool.

On prevention, the guidelines are unequivocal that standardized radical treatment of the primary colorectal cancer remains the most effective strategy for reducing liver metastasis risk. For colon cancer, this means complete mesocolic excision with adequate proximal and distal margins and removal of the associated mesentery and lymphatic drainage. For rectal cancer, total mesorectal excision is mandatory for mid and lower tumors. The update also embraces neoadjuvant approaches aimed at eradicating micrometastases invisible to imaging. For patients with deficient mismatch repair or microsatellite instability-high rectal cancer, immune checkpoint inhibitors can achieve such favorable outcomes that many patients may avoid surgery altogether through a watch-and-wait approach. For proficient mismatch repair tumors staged T3 or higher, or with positive lymph nodes, neoadjuvant radiotherapy, chemoradiotherapy or chemotherapy is recommended, and total neoadjuvant treatment is endorsed as an option that increases complete response rates and facilitates organ preservation.

The multidisciplinary team model receives a Grade A recommendation for all patients with colorectal liver metastases. The guidelines specify that the team should include colorectal or gastrointestinal surgeons, hepatobiliary surgeons, medical oncologists, radiation oncologists, interventional radiologists, diagnostic radiologists, ultrasound specialists and pathologists. The documented advantages of this approach include more accurate molecular profiling, more precise staging, fewer treatment delays, more individualized treatment planning, improved coordination, enhanced quality of life, better survival outcomes and superior cost-effectiveness. The MDT framework is then used to stratify patients into distinct therapeutic pathways: those with initially resectable metastases, those with potentially convertible disease, and those whose metastases will never be resectable, each with tailored goals ranging from cure to disease control.

Surgical treatment remains the gold standard for cure, and the 2025 edition reflects how far the boundaries of resectability have expanded. Surgical decisions are no longer restricted by tumor size, number or location alone. The guidelines now support resection with margins smaller than one centimeter, resection of hepatic pedicle lymph node metastases, and resection of resectable extrahepatic disease including pulmonary and peritoneal metastases. For patients with insufficient future liver remnant volume, the guidelines describe a sophisticated arsenal of techniques: portal vein embolization to induce compensatory hypertrophy, the ALPPS procedure for rapid remnant growth, liver venous deprivation as a less invasive alternative, and selective internal radiation therapy with yttrium-90 microspheres, which can shrink tumors while simultaneously stimulating growth of the untouched liver lobe. Liver transplantation combined with systemic therapy is cautiously endorsed for selected patients with liver-limited disease that cannot achieve no evidence of disease status despite multimodal treatment, an approach supported by the recent TransMet randomized trial showing significantly improved overall survival.

For unresectable disease, the guidelines detail an escalating therapeutic ladder. First-line chemotherapy combines fluoropyrimidines with oxaliplatin and/or irinotecan, with molecular targeted agents such as bevacizumab or cetuximab added to increase conversion to resectability. Triplet FOLFOXIRI regimens are endorsed for fit patients when targeted therapy is contraindicated. For tumors with deficient mismatch repair, immune checkpoint inhibitors such as pembrolizumab or the nivolumab-ipilimumab combination are the preferred first-line approach, having demonstrated significantly improved disease control and conversion rates compared with chemotherapy. Maintenance therapy with low-toxicity regimens after induction, sequential switching between FOLFOX and FOLFIRI upon progression, and later-line options including trifluridine/tipiracil, regorafenib and fruquintinib are all codified. Local therapies including radiofrequency ablation for lesions under three centimeters, microwave ablation for lesions under five centimeters, and stereotactic body radiotherapy for oligometastatic disease round out the comprehensive toolkit, ensuring that even patients whose metastases can never be removed can still expect meaningful prolongation of survival and quality of life.

Subject of Research: Clinical guidelines for the diagnosis and comprehensive treatment of colorectal cancer liver metastases

Article Title: Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastasis (2025 Edition)

Article References: Fan, J., Gu, J., Jia, B., Li, J., Qin, X., Wang, X., Xu, J., Xu, R., Ye, Y., Zhang, S., Zhang, Z., & Chinese College of Surgeons, Chinese Medical Doctor Association (CMDA); Gastrointestinal Surgery Group, Chinese Society of Surgery, Chinese Medical Association (CMA); Colorectal Surgery Group, Chinese Society of Surgery, CMA; Colorectal Cancer Professional Committee, Chinese Anti-Cancer Association; Colorectal Cancer Professional Committee, CMDA; Colorectal Cancer Expert Committee, Chinese Society of Clinical Oncology; Colorectal Surgeon Committee, Chinese College of Surgeons, CMDA; Metastasis Research Com (2026). Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastasis (2025 Edition). Clinical Cancer Bulletin, 5(1), Article 10. https://doi.org/10.1007/s44272-026-00062-6

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00062-6

Keywords: colorectal cancer, liver metastases, clinical guidelines, immunotherapy, hepatic surgery, molecular profiling, chemotherapy, multidisciplinary team, precision medicine, radiofrequency ablation, liver transplantation, biomarkers

Cervical cancer is largely preventable through vaccination against human papillomavirus and detectable early through screening, yet it remains a major source of cancer deaths worldwide, particularly in low- and middle-income countries where screening programs are limited. For the subset of women whose disease recurs after treatment of the primary tumor or who present with metastatic disease at diagnosis, prognosis has historically been bleak. The mainstay of treatment for decades was combination chemotherapy, with or without the anti-angiogenic agent bevacizumab, which could slow the disease temporarily but rarely produced long-term control. Median survival in this setting had for years remained measured in months rather than years.

That landscape began to shift as researchers recognized that cervical cancer, despite being a virally driven malignancy, had characteristics that made it potentially susceptible to immune checkpoint blockade. Pembrolizumab, a monoclonal antibody that blocks the programmed cell death protein 1, or PD-1, receptor on T cells, releases a molecular brake that tumors use to disable the immune response. By preventing PD-1 from engaging its ligands, the drug allows cytotoxic T lymphocytes to recognize and attack tumor cells. The rationale for testing the drug in cervical cancer was reinforced by the observation of tumor-associated T-cell infiltration and the activity of pembrolizumab as a single agent in previously treated patients, which paved the way for a definitive test in the first-line, untreated setting.

KEYNOTE-826, the trial behind the new analysis, enrolled patients with persistent, recurrent, or metastatic cervical cancer who had not previously received systemic chemotherapy for their advanced disease. Participants were randomly assigned to receive their physician’s choice of standard chemotherapy, with or without bevacizumab, either alone or in combination with pembrolizumab. The trial used a double-blind, placebo-controlled design, meaning that neither patients nor the investigators assessing outcomes knew which treatment arm each patient had been assigned to, a rigor that strengthens the reliability of the comparisons. The study was stratified in ways that reflected known prognostic variables, including the use of bevacizumab, prior exposure to radiotherapy, tumor histology with separate accounting for squamous and adenocarcinoma subtypes, and PD-L1 expression status as determined by a validated combined positive score.

The initial reports of the trial demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of overall survival and progression-free survival, along with higher response rates, among patients receiving pembrolizumab plus chemotherapy compared with chemotherapy alone. Those results led to regulatory approvals in the United States and elsewhere and changed practice guidelines internationally. Immunotherapy combinations, however, carry a distinctive uncertainty: unlike cytotoxic chemotherapy, whose effects are usually immediate and short-lived, immune-mediated responses can be durable but take time to fully manifest. The central question addressed by extended follow-up is whether the survival curves remain separated over many years, whether a meaningful fraction of patients remain progression-free long after treatment ends, and whether late toxic effects erode the benefit.

The five-year data reported in the new analysis provide reassurance on all three counts. The separation between treatment arms observed in earlier interim analyses persisted with longer follow-up, and the durability of benefit supports the interpretation that the early advantage was not an artifact of immature data. Patients with PD-L1-positive tumors, who represent the majority of those with advanced cervical cancer, derived particular benefit, consistent with the biological expectation that checkpoint blockade works best when the tumor microenvironment already harbors an immune response that has been suppressed rather than one that is absent altogether. The analysis also confirmed that the safety profile remained consistent with what had been established previously, without the emergence of concerning late-onset adverse events that would complicate the risk-benefit calculus.

For clinicians treating gynecologic cancers, the confirmation matters because it removes lingering doubt about whether to incorporate pembrolizumab into first-line treatment. When overall survival benefits are demonstrated at interim analyses with limited follow-up, some physicians defer adoption pending proof of durability, particularly when the regimen adds cost, requires regular infusions, and carries the risk of immune-related adverse events affecting organs such as the thyroid, lungs, colon, and kidneys. Five-year data showing that patients who received the combination were still alive and, in some cases, still without disease progression years after randomization provide the kind of evidence that persuades even cautious practitioners and health systems to make the regimen standard of care.

The findings also carry implications for how the field moves forward. With an immunotherapy-chemotherapy backbone now established as the foundation of first-line treatment for recurrent and metastatic cervical cancer, research attention is turning to questions the original trial was not designed to answer. These include whether biomarkers beyond PD-L1 expression can identify which patients stand to benefit most, whether the addition of bevacizumab is necessary for all patients or can be reserved for selected groups, whether novel agents such as antibody-drug conjugates can be layered onto the regimen safely, and whether patients who achieve long-term disease control can safely discontinue treatment. Trials exploring tissue-agnostic and site-specific combinations are already underway, building on the platform that KEYNOTE-826 validated.

There are limits to what even long-term randomized data can resolve. The exploratory nature of this analysis means that some subgroup findings should be interpreted with caution, as smaller patient numbers reduce statistical power and increase the chance that observed differences reflect chance rather than biology. Access remains a critical concern: pembrolizumab is expensive, and the populations with the highest burdens of cervical cancer often live in health systems where the drug is least available. Translating a five-year survival benefit demonstrated in an international trial into widespread clinical reality requires attention to drug pricing, health infrastructure, and the upstream interventions of HPV vaccination and screening that prevent advanced disease in the first place.

Nevertheless, the five-year results represent a milestone for a disease that, until recently, offered patients with recurrence little hope of extended survival. The demonstration that benefit endures converts an important interim finding into a settled standard and provides a reference point against which all future therapies for advanced cervical cancer will be measured. For the women treated on the trial, the data translate into years of life that would likely have been lost under the previous standard, and for the broader oncology community, they reinforce a principle that has gradually reshaped cancer medicine: when the immune system can be durably unleashed against a tumor, the benefits can outlast the treatment itself. The corresponding author of the analysis is Kosei Hasegawa, MD, PhD, of the Department of Gynecologic Oncology at Saitama Medical University International Medical Center in Japan, and the findings were published in JAMA Oncology under DOI 10.1001/jamaoncol.2026.3547.

Subject of Research: Pembrolizumab combined with chemotherapy as first-line treatment for recurrent and metastatic cervical cancer

Article Title: Pembrolizumab plus chemotherapy for cervical cancer

Article References: Pembrolizumab plus chemotherapy for cervical cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cervical cancer, pembrolizumab, KEYNOTE-826, immunotherapy, PD-1 inhibitor, chemotherapy, bevacizumab, JAMA Oncology, metastatic cancer, clinical trial, overall survival, gynecologic oncology

The drug targets the phosphatidylinositol-4,5-bisphosphate 3-kinase, AKT, mechanistic target of rapamycin signaling cascade, a central growth and survival pathway that is frequently dysregulated in both canine and human cancers. When this pathway runs amok, it drives neoplastic cells to proliferate relentlessly, evade apoptosis, crank up metabolism, and, in the case of lymphoid malignancies, stimulate the production of vascular endothelial growth factor, a molecule that supports tumor neovascularization. Because single-node inhibitors of the pathway often deliver only brief or incomplete responses, likely due to well-known feedback loops within the signaling network, the researchers turned to VDC597, a compound that blocks PI3K along with both mTOR complexes, mTORC1 and mTORC2, thereby hitting the pathway at multiple points simultaneously.

In their experiments, the team tested VDC597 against two canine cell lines: 1771, derived from a spontaneously occurring B-cell lymphoma, and CLL1390, derived from chronic lymphocytic leukemia. Both lines had previously been documented to carry mutations in or constitutively express activated proteins of the PI3K-AKT-mTOR pathway, making them appropriate models for pathway-targeted therapy. Western blot analysis showed that a 24-hour treatment with the drug produced a clear, dose-dependent reduction in phosphorylated AKT at the serine 473 residue, the molecular signature of pathway activation. The leukemia line proved more sensitive, showing significant suppression at concentrations as low as 0.2 micromolar, while the lymphoma line required a full micromolar dose to achieve statistically significant inhibition.

Timing experiments revealed that the drug’s effects on signal transduction are both rapid and durable. Following a single 1 micromolar dose, phosphorylation of AKT dropped quickly and remained at roughly half of control levels for a full 24 hours. Downstream phosphorylation of 4EBP1, a translation-regulating target of mTORC1, fell even more sharply, with statistically significant suppression measurable from half an hour after treatment through the two-hour mark. The researchers verified these biochemical findings by immunohistochemistry on fixed cell pellets, observing reduced perinuclear and cytoplasmic staining for both phosphoproteins after drug exposure, an encouraging confirmation that the compound shuts down signaling across the entire pathway rather than just a single branch.

The functional consequences were equally striking. After 72 hours of exposure, VDC597 halved the viable cell population at concentrations within or near what is pharmacologically achievable, with mean half-maximal inhibitory concentrations of 1.41 micromolar for CLL1390 and 2.56 micromolar for 1771, values informed by an earlier phase I trial of the drug in tumor-bearing dogs. Live-cell imaging, tracking fluorescently labeled nuclei and dead-cell stains over 48 hours, showed that the drug did not merely slow proliferation: it actively killed the lymphoma cells, with cell death increasing in a dose-dependent manner and becoming significantly elevated at concentrations of 0.25 micromolar and above. Enzyme-linked immunosorbent assays further demonstrated that VDC597 suppressed vascular endothelial growth factor production in both cell lines, again in a dose-dependent fashion, suggesting the drug may undermine the angiogenic support system that lymphoid tumors rely upon.

Because combination therapy, not single agents, ultimately determines how well targeted drugs translate into clinical benefit, the team paired VDC597 with the three chemotherapy drugs most commonly used in canine lymphoma protocols: dexamethasone, doxorubicin, and vincristine. The results were revealing. Combining VDC597 with dexamethasone produced genuinely synergistic growth inhibition, quantified by combination indices below 1 using the Chou-Talalay method, with the effect strongest at lower drug concentrations. Pairing the drug with doxorubicin yielded additive to mildly synergistic effects at lower doses, though the highest doxorubicin concentration produced antagonism, possibly because PI3K inhibition dampens the reactive oxygen species generation through which doxorubicin promotes apoptosis. Vincristine, whose mechanism overlaps with the pathway’s role in microtubule function during mitosis, showed only additive to mildly antagonistic interactions.

The strong synergy with dexamethasone is mechanistically compelling. Glucocorticoids kill lymphoid cells through receptors whose nuclear translocation and downstream signaling are potentiated by PI3K-AKT-mTOR inhibition, a finding previously documented in human B-cell acute lymphoblastic leukemia. The Colorado State results thus support the hypothesis that adding a dual PI3K/mTOR inhibitor to standard chemotherapy could deepen responses or sensitize resistant tumors, particularly in lymphoma, where the clinical reservoir of effective options is thin.

Importantly, the study went beyond cell culture to examine pathway activation in actual patients. Using tissue microarrays built from 118 lymph node samples collected from 84 dogs with spontaneous B-cell lymphoma, the researchers scored phosphorylated AKT and phosphorylated 4EBP1 by immunohistochemistry, employing both traditional manual Allred scoring and artificial intelligence-assisted whole-slide analysis with Visiopharm software to generate finer-grained H-scores. The two approaches correlated well, validating the use of machine learning tools for quantitative pathology in veterinary specimens. The phosphorylation signals proved highly variable from tumor to tumor, underscoring that not every canine B-cell lymphoma is driven by an equally active PI3K-AKT-mTOR pathway.

Two clinically meaningful correlations emerged. First, tumors with lower expression of major histocompatibility complex class II, a known adverse prognostic marker measured by flow cytometry, showed significantly higher levels of phosphorylated AKT, linking aggressive immune phenotype to stronger pathway activity. Second, samples taken after relapse following CHOP chemotherapy showed higher phosphorylated 4EBP1 than matched pre-treatment samples, a result that retained significance in paired manual scoring. However, no correlation was found between either phosphoprotein and progression-free interval, overall survival, WHO stage or substage, or flow cytometric immunophenotypic markers, and phosphorylated AKT did not rise in parallel with phosphorylated 4EBP1 in the relapse samples. The authors caution against overinterpreting these limited associations and suggest several possible explanations, including AKT phosphorylation at sites not detected by the assay, alternative 4EBP1 kinases such as PIM2 or RAS/MAPK signaling, or mutations downstream of AKT.

The study has clear limitations that its authors acknowledge. Only one cell line each was tested for lymphoma and leukemia, so the full heterogeneity of canine lymphoid malignancies, including T-cell lymphoma and acute lymphoblastic leukemia, remains unexplored. No washout experiments were performed to determine how long signaling stays suppressed after the drug is withdrawn, information that would be essential for designing oral dosing schedules. And the finding of elevated phosphorylated 4EBP1 without corresponding phosphorylated AKT in relapsed tumors awaits mechanistic confirmation. Nevertheless, the core message is clear: VDC597 collapses PI3K-AKT-mTOR signaling, kills lymphoid cancer cells in vitro at achievable concentrations, synergizes with dexamethasone, and may sensitize tumors to standard chemotherapy. As dogs with spontaneous diffuse large B-cell lymphoma are increasingly recognized as valuable models for human non-Hodgkin lymphoma, these results position dual PI3K/mTOR inhibition as a strategy worth advancing toward larger cell line panels, animal studies, and ultimately clinical trials in both species.

Subject of Research: Evaluation of the dual PI3K/mTOR inhibitor VDC597 against canine B-cell lymphoma and chronic lymphocytic leukemia cells in vitro, with immunohistochemical assessment of PI3K-AKT-mTOR pathway activation in spontaneous canine B-cell lymphoma.

Article Title: In vitro effects of the PI3K/mTOR dual-inhibitor, VDC597, in canine lymphoma and leukemia

Article References: Meuten, T., Brill, S. A., Brady, R. V., Farrell, K. B., Rose, B. J., Schlein, L. J., & Thamm, D. H. (2026). In vitro effects of the PI3K/mTOR dual-inhibitor, VDC597, in canine lymphoma and leukemia. Veterinary Oncology, 3(1), Article 13. https://doi.org/10.1186/s44356-026-00065-4

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00065-4

Keywords: canine lymphoma, canine leukemia, VDC597, PI3K, mTOR, AKT, 4EBP1, signal transduction, chemotherapy, immunohistochemistry, veterinary oncology, drug combination

Colorectal cancer remains one of the most common malignancies worldwide, and while radical surgery is highly effective when the disease has not spread to distant organs, stage III disease, defined by lymph node involvement, carries a recurrence rate of 20 to 30 percent. Adjuvant chemotherapy after surgery has been proven in randomized controlled trials to reduce this risk and improve survival. However, the picture becomes murkier in patients aged 70 and older. As people age, comorbidities accumulate and organ function declines, making chemotherapy harder to tolerate and raising the risk of serious adverse events. Notably, there is no consistent evidence that adding oxaliplatin provides additional benefit in this age group, suggesting that the therapeutic effect of adjuvant chemotherapy may be limited for many elderly patients.

This uncertainty creates a real clinical dilemma. Physicians must weigh the possibility of a survival benefit against the substantial burden chemotherapy can impose on an older body. The Japanese research team, led by Tomoya Tago and Yasuyuki Takamizawa, set out to determine whether simple blood-derived markers, calculated from tests already ordered in routine care, could identify which elderly patients are most likely to benefit from postoperative chemotherapy and which might safely avoid it.

The study included patients aged 70 or older who underwent radical resection of pathologically confirmed stage III colorectal adenocarcinoma at the National Cancer Center Hospital between January 2000 and December 2017. After excluding those with other primary cancers, prior neoadjuvant therapy, or incomplete data, 308 patients remained, of whom 177 received adjuvant chemotherapy and 131 did not. Because patients selected for chemotherapy were significantly younger and likely healthier than those who were not, the researchers used propensity score matching to balance the two groups on sex, age, body mass index, comorbidities, tumor location and stage, histology, and preoperative tumor marker levels. This produced 78 matched pairs with well-balanced baseline characteristics.

The survival benefit of adjuvant chemotherapy held up after matching. The five-year recurrence-free survival rate was 76.6 percent in the chemotherapy group versus 62.8 percent in the non-treatment group, with a hazard ratio of 0.537. Five-year overall survival was 84.1 percent versus 73.9 percent, with a hazard ratio of 0.495. Both differences were statistically significant, confirming that adjuvant chemotherapy remains worthwhile for properly selected elderly patients overall.

The most striking findings emerged when the researchers stratified the matched cohort by nine preoperative and postoperative immuno-nutritional and inflammatory markers, including the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index, geriatric nutritional risk index, controlling nutritional status score, Glasgow Prognostic Score, and modified Glasgow Prognostic Score. Two postoperative markers showed significant interactions with chemotherapy benefit: the lymphocyte-to-monocyte ratio and the C-reactive protein-to-albumin ratio.

In patients with a high postoperative LMR, defined by the study’s cut-off of 5.27, adjuvant chemotherapy produced a dramatic improvement. Five-year recurrence-free survival reached 84.4 percent in the treated group versus just 53.0 percent in the untreated group, a hazard ratio of 0.27. Overall survival showed an even starker contrast: 92.1 percent versus 68.0 percent, with a hazard ratio of 0.16. Yet in patients with a low postoperative LMR, chemotherapy provided essentially no advantage, with five-year recurrence-free survival of 69.2 percent versus 72.9 percent, and overall survival of 76.9 percent versus 80.4 percent, both comparisons statistically indistinguishable.

The CAR told a similar story. Patients with a high postoperative CAR, above the cut-off of 0.026, derived marked benefit from chemotherapy, with five-year recurrence-free survival of 79.0 percent versus 47.8 percent and overall survival of 88.0 percent versus 62.4 percent. In those with a low CAR, the survival curves of treated and untreated patients were nearly superimposable. The biological rationale is rooted in tumor-host interactions: lymphocytes mount anti-tumor immune responses and their preservation is associated with better drug responsiveness, whereas systemic inflammation, marked by elevated C-reactive protein relative to albumin, reflects a cytokine-driven state regulated by interleukin-1, interleukin-6, and tumor necrosis factor-alpha that generally portends poorer outcomes. Because postoperative samples in this study were collected uniformly four to eight weeks after surgery, once acute inflammatory responses from the operation had subsided, the markers likely captured the patient’s intrinsic baseline immunity at the moment chemotherapy would begin, rather than residual tumor-driven inflammation.

The clinical appeal of these markers lies in their simplicity and cost. Unlike circulating tumor DNA, which shows promise for predicting treatment efficacy but remains expensive and not yet widely implementable, LMR and CAR can be calculated from standard complete blood counts and chemistry panels already obtained in routine follow-up. The authors suggest that these values could serve as supplementary information alongside age, performance status, and comorbidities when the indication for adjuvant chemotherapy is being considered, helping individualize decisions rather than uniformly determine them.

The researchers acknowledge important limitations. The study was retrospective and single-center, so selection bias and institution-specific treatment practices cannot be fully excluded, and the derived cut-off values may not generalize elsewhere. Standardized comorbidity assessment tools such as the Charlson Comorbidity Index and Geriatric-8 were not consistently available, data on chemotherapy completion rates and adverse events were incomplete, and molecular information on RAS, BRAF, and microsatellite instability status was lacking for much of the study period. Even so, because the cohort included elderly patients with common comorbidities, it reflects a population closer to real-world practice than the highly selected patients enrolled in clinical trials. The authors conclude that postoperative LMR and CAR are promising predictors of adjuvant chemotherapy efficacy in this growing patient population and hope the work will spur development of novel biomarkers for guiding treatment decisions in elderly cancer care.

Subject of Research: Predicting adjuvant chemotherapy efficacy in elderly stage III colorectal cancer patients using immuno-nutritional and inflammatory blood markers

Article Title: Predicting the Efficacy of Adjuvant Chemotherapy Using Immuno‐Nutritional and Inflammatory Markers in Elderly Patients With Stage III Colorectal Cancer

Article References: Tago, T., Takamizawa, Y., Kato, T., Nagata, H., Moritani, K., Tsukamoto, S., & Kanemitsu, Y. (2026). Predicting the Efficacy of Adjuvant Chemotherapy Using Immuno‐Nutritional and Inflammatory Markers in Elderly Patients With Stage III Colorectal Cancer. Annals of Gastroenterological Surgery, 10(5), 1575-1585. https://doi.org/10.1002/ags3.70235

Image Credits: AI Generated

DOI: 10.1002/ags3.70235

Keywords: colorectal cancer, adjuvant chemotherapy, elderly patients, lymphocyte-to-monocyte ratio, C-reactive protein-to-albumin ratio, immuno-nutritional markers, inflammatory markers, propensity score matching, recurrence-free survival, biomarkers, National Cancer Center Hospital, Annals of Gastroenterological Surgery

The patient’s blood counts told the first part of the story. He was severely anemic and profoundly neutropenic, with an absolute neutrophil count of just 150 cells per microliter—far below the threshold of 500 cells per microliter that clinicians regard as a major risk factor for invasive aspergillosis. Neutrophils are the body’s first line of defense against filamentous fungi, engulfing and destroying inhaled spores before they can germinate into invasive hyphae. When chemotherapy strips that defense away, ubiquitous environmental molds that most people breathe in daily without consequence can colonize and invade tissue with alarming speed. Prolonged neutropenia lasting more than 20 days is among the strongest known predisposing factors, and the cumulative risk of invasive aspergillosis climbs to roughly 70 percent after 34 days of persistent neutropenia in vulnerable patients.

What happened next is what makes this case remarkable. A chest computed tomography scan revealed a mass-like lesion along the posterior wall of the trachea, just below the suprasternal notch. Critically, the scan showed no evidence of involvement of the lung parenchyma itself—the tissue where pulmonary aspergillosis almost always announces itself. Invasive pulmonary aspergillosis, the most feared form of the disease, typically produces nodules, halos of hemorrhage, or cavitary lesions within the lung tissue, and radiologists use these patterns to guide early treatment. Here, the lungs appeared spared. The infection had instead declared itself as a solitary, obstructing lesion inside the central airway, a pattern that mimics an endobronchial tumor or an aspirated foreign body far more than a fungal infection.

Flexible bronchoscopy settled the question of what was occupying the trachea, though not before revealing how dangerous the situation had become. The scope encountered a whitish, irregular endoluminal mass with elongated, intertwined projections and a pseudomembranous appearance—classic visual features of fungal growth—situated in the mid-trachea. The lesion was obstructing enough that the bronchoscope could not be advanced beyond it, meaning the medical team could not visually assess the distal airways for further disease, mucus impaction, or more extensive tracheobronchial involvement. Notably, the visible mucosa showed no overt invasion, necrosis, or active bleeding, and biopsies were taken without complication.

Laboratory analysis of the sampled tissue provided the definitive answer. Microscopy demonstrated septate hyphae branching at acute angles of approximately 45 degrees—the morphological signature of Aspergillus species—and polymerase chain reaction testing confirmed Aspergillus fumigatus as the causative organism. That identification is hardly surprising from an epidemiological standpoint: A. fumigatus accounts for more than 90 percent of human aspergillosis cases. The fungus is found everywhere—soil, decaying vegetation, water, food, and air—and infects hosts almost exclusively through inhalation of airborne spores, which helps explain why the respiratory tract bears the brunt of disease. Research also suggests A. fumigatus adheres to airway epithelium more effectively than related species such as A. flavus or A. niger, potentially giving it a particular advantage in colonizing the tracheobronchial tree.

Treatment was initiated promptly with amphotericin B and voriconazole, the workhorse antifungals for invasive aspergillosis. It did not matter. The patient deteriorated rapidly and died of respiratory failure within 36 hours of diagnosis. The authors of the report acknowledge that the precise mechanism of this fulminant collapse remains uncertain. The obstructing tracheal lesion itself likely played a central role—endobronchial fungal proliferation can critically narrow the airway lumen and precipitate respiratory failure—but the inability to examine beyond the obstruction means distal airway spread could not be excluded. In a patient with essentially no neutrophil defense, the authors note, multiple converging factors may have driven the fatal outcome.

The rarity of this presentation underscores its diagnostic difficulty. Endobronchial aspergillosis, defined by endoluminal fungal growth within the tracheobronchial tree, is an uncommon manifestation of Aspergillus disease. A 2019 review by Ngu and colleagues identified only 28 documented cases worldwide, most occurring in Asian males with a mean age of 58 years, and a separate series described by Huang and colleagues found 17 cases with similar demographics. The condition is frequently discovered incidentally during bronchoscopy performed for other reasons, such as evaluating hemoptysis. Symptoms—fever, breathlessness, chest pain, cough, and bleeding—are nonspecific, and risk factors include any form of immunosuppression as well as underlying lung disease. In a 2011 series of ten patients reported by Ma and colleagues, all had identifiable predisposing conditions such as tuberculosis, lung cancer, or foreign body aspiration, and only two had concurrent parenchymal lung involvement, a pattern echoed by the present case.

The stakes of missing or delaying diagnosis are stark. Among patients with severe airway aspergillosis who require mechanical ventilation, mortality reaches 94 percent, compared with 25 percent among those who do not—a difference that reflects both advanced disease at presentation and the mechanical consequences of airway obstruction. Diagnosis itself is far from straightforward. The traditional gold standard, fungal culture, is limited by the difficulty of obtaining adequate samples from hemodynamically unstable patients, by coagulopathies such as thrombocytopenia that make biopsy risky, and by false-negative results in patients already receiving antifungal therapy. Indirect methods fill some of the gap: galactomannan detection in serum or bronchoalveolar lavage fluid shows reasonable reliability in hematologic malignancy, though its sensitivity ranges widely from 44 to 90 percent, and false positives occur with certain antibiotics and with dimorphic fungal infections. Beta-D-glucan testing, meanwhile, lacks specificity for aspergillosis altogether.

Treatment of endobronchial aspergillosis remains unstandardized, with management individualized case by case. Most clinicians favor combining systemic antifungal therapy with interventional bronchoscopy to debulk obstructing lesions, and favorable outcomes have been reported with bronchoscopically guided resection combined with drug therapy. Some experts have argued for conservative approaches, noting that systemic agents may penetrate airway lesions poorly, while intolerance or resistance to azoles, or competing infections, can push clinicians toward surgical resection. The pharmacology is also evolving: liposomal amphotericin B carries less nephrotoxicity than the deoxycholate formulation, but adverse effects including renal tubular acidosis, hypomagnesemia, and hypokalemia have shifted general clinical preference toward azoles and echinocandins for pulmonary disease.

The authors are candid about the limits of their own report. Histopathological assessment was confined to the obstructing endoluminal lesion; because of the patient’s critical condition and the risk of procedure-related complications, no biopsies were taken from the tracheal wall or cartilage. That means direct evidence of mucosal, submucosal, or cartilaginous invasion was never obtained, and the lesion could not be definitively classified as invasive or necrotizing tracheobronchitis rather than more superficial endobronchial disease. The pseudomembranous bronchoscopic appearance, the profound neutropenia, and the explosively fatal course all hint at a more aggressive process, but certainty was impossible. What the case establishes beyond doubt is the clinical lesson the authors emphasize: endobronchial Aspergillus infection belongs on the differential for any immunocompromised patient with airway obstruction, even when chest imaging shows the lungs themselves are clear. In this patient, an isolated tracheal lesion—invisible to the usual radiologic playbook—was enough to kill within two days of identification, a reminder that in the profoundly neutropenic host, the absence of parenchymal disease offers no reassurance at all.

Subject of Research: A fatal case of isolated endobronchial Aspergillus fumigatus infection in a neutropenic lymphoma patient without lung parenchymal involvement

Article Title: Endobronchial Aspergillosis Presenting as an Isolated Airway Lesion in an Immunocompromised Patient

Article References: Sadeghi, M., Sadat Hosseini Khajouei, F., GhanbarAliAkhavan, H., & Soleimani, A. M. (2026). Endobronchial Aspergillosis Presenting as an Isolated Airway Lesion in an Immunocompromised Patient. Respirology Case Reports, 14(9), Article e70701. https://doi.org/10.1002/rcr2.70701

Image Credits: AI Generated

DOI: 10.1002/rcr2.70701

Keywords: aspergillosis, Aspergillus fumigatus, endobronchial aspergillosis, neutropenia, immunocompromised, bronchoscopy, tracheal obstruction, invasive fungal infection, lymphoma, chemotherapy, respiratory failure, case report